Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains

Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2003, Pages 1764-1768

  Tamamura, Hirokazu ^a   Koh, Yasuhiro ^b   Ueda, Satoshi ^a   Sasaki, Yoshikazu ^a   Yamasaki, Tomonori ^a   Aoki, Manabu ^b   Maeda, Kenji ^b   Watai, Yoriko ^c   Arikuni, Hisashi ^c   Otaka, Akira ^a   Mitsuya, Hiroaki ^b,d   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c Yokohama Laboratory   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TYA5; TYB1; TYB5; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; VIRUS INHIBITION;

DIPEPTIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; ISOQUINOLINES; MOLECULAR MIMICRY; NAPHTHALENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0344519605     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020537i     Document Type: Article

References (21)

1. Rich, D. H.; Green, J.; Toth, M. V.; Marshall, G. R.; Kent, S. B. H. Hydroxyethylamine Analogues of the p17/p24 Substrate Cleavage Site Are Tight-Binding Inhibitors of HIV Protease. J. Med. Chem. 1990, 33, 1285-1288.
2. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational Design of Peptide-Based HIV Proteinase Inhibitors. Science 1990, 248, 358-361.
3. Parkes, K. E. B.; Bushnell, D. J.; Crackett, P. H.; Dunsdon, S. J.; Freeman, A. C.; Gunn, M. P.; Hopkins, R. A.; Lambert, R. W.; Martin, J. A.; Merrett, J. H.; Redshaw, S.; Spurden, W. C.; Thomas, G. J. Studies toward the Large-Scale Synthesis of the HIV Proteinase Inhibitor Ro 31-8959. J. Org. Chem. 1994, 59, 3656-3664.
4. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100,
5. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 Is a Potent Inhibitor of Human Immunodeficiency Virus Protease and Has High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
6. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. R. Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
7. Kaldor, S. W.; Kalish, V. J.; Davies, J. F., II.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. J. Med. Chem. 1997, 40, 3979-3985.
8. Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Walters, D. E.; Krishnan, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-(Hydroxyethylamino)sulfonamide Isostere. Bioorg. Med. Chem. Lett. 1998, 8, 687-690.
9. Mimoto, T.; Kato, R.; Takaku, H.; Nojima, S.; Terashima, K.; Misawa, S.; Fukazawa T.; Ueno, T.; Sato, H.; Shintani, M.; Kiso, Y.; Hayashi, H. Structure-Activity Relationship of Small-Sized HIV Protease Inhibitors. J. Med. Chem. 1999, 42, 1789-1802.
10. Mitsuya, H.; Erickson, J. Discovery and Development of Antiretroviral Therapeutics for HIV Infection. In Textbook of AIDS Medicine; Merigan, T. C., Bartlett, J. G., Bolognesi, D., Eds.; Williams & Wilkins: Baltimore, 1999; pp 751-780.
11. Tamamura, H.; Hiramatsu, K.; Miyamoto, K.; Omagari, A.; Oishi, S.; Nakashima, H.; Yamamoto, N.; Kuroda, Y.; Nakagawa, T.; Otaka, A.; Fujii, N. Synthesis and Evaluation of Pseudopeptide Analogues of a Specific CXCR4 Inhibitor, T140: The Insertion of an (E)-Alkene Dipeptide Isostere into the βII′-Turn Moiety. Bioorg. Med. Chem. Lett. 2002, 12, 923-928.
12. Tamamura, H.; Hori, T.; Otaka, A.; Fujii, N. Efficient Stereo-selective Synthesis of Peptidomimetics Containing Hydroxyethylamine Dipeptide Isosteres Utilizing the Aza-Payne Rearrangement and O, N-Acyl Transfer Reactions. J. Chem. Soc., Perkin Trans. 1 2002, 577-580.
13. 3 Ligands. J. Med. Chem. 1996, 39, 96-108.
14. Sham, H. L.; Betebenner, D. A.; Zhao, C.; Wideburg, N. E.; Saldivar, A.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. Facile Synthesis of Potent HIV-1 Protease Inhibitors Containing a Novel Pseudo-symmetric Dipeptide Isostere. J. Chem. Soc., Chem. Commun. 1993, 1052-1053.
15. Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere. J. Med. Chem. 1993, 36, 288-291.
16. Barrish, J. C.; Gordon, E.; Alam, M.; Lin, P.-F.; Bisacchi, G. S.; Chen, P.; Cheng, P. T. W.; Fritz, A. W.; Greytok, J. A.; Hermsmeier, M. A.; Humphreys, W. G.; Lis, K. A.; Marella, M. A.; Merchant, Z.; Mitt, T.; Morrison, R. A.; Obermeier, M. T.; Pluscec, J.; Skoog, M.; Slusarchyk, W. A.; Spergel, S. H.; Stevenson, J. M.; Sun, C.; Sundeen, J. E.; Taunk, P.; Tino, J. A.; Warrack, B. M.; Colonno, R. J.; Zahler, R. Aminodiol HIV Protease Inhibitors. 1. Design, Synthesis and Preliminary SAR. J. Med. Chem. 1994, 37, 1758-1768.
17. Tamamura, H.; Yamashita, M.; Nakajima, Y.; Sakano, K.; Otaka, A.; Ohno, H.; Ibuka, T.; Fujii, N. Regiospecific Ring-opening Reactions of β-Aziridinyl α,β-Enoates with Acids: Application to the Stereoselective Synthesis of a Couple of Diastereoisomeric (E)-Alkene Dipeptide Isosteres from a Single β-Aziridinyl α,β-Enoate and to the Convenient Preparation of Amino Alcohols Bearing α,β-Unsaturated Ester Groups. J. Chem. Soc., Perkin Trans. 1 1999, 2983-2996.
18. Yoshimura, K.; Kato, R.; Kavlick, M. F.; Nguyen, A.; Maroun, V.; Maeda, K.; Hussain, K. A.; Ghosh, A. K.; Gulnik, S. V.; Erickson, J. W.; Mitsuya, H. A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site. J. Virol. 2002, 76, 1349-1358.
19. Kuwata, H.; Yip, T.-T.; Yip, C. L.; Tomita, M.; Hutchens, T. W. Bactericidal Domain of Lactoferrin: Detection, Quantitation and Characterization of Lactoferricin in Serum by SELDI Affinity Mass Spectrometry. Biochem. Biophys. Res. Commun. 1998, 245, 764-773.
20. Turner, R. T., III.; Koelsch, G.; Hong, L.; Castanheira, P.; Ghosh, A.; Tang, J. Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design. Biochemistry 2001, 40, 10001-10006.
21. Rich, D. H.; Bursavich, M. G.; Estiarte, M. A. Discovery of Nonpeptide, Peptidomimetic Peptidase Inhibitors that Target Alternate Enzyme Active Site Conformations. Biopolymers 2002, 66, 115-125.